Roche Chairman Christoph Franz remains confident the Swiss drugmaker can offset revenue declines from patent expired medicines with new drugs, according to an interview published on Sunday in the Swiss newspaper NZZ am Sonntag.
“When I look at the number of medicines we have launched over the past two years, then we’re on the right track,” Franz told the newspaper. “We’ve had six medicines approved by regulators over this time period.”
Among the drugs Franz includes in this group are multiple sclerosis drug Ocrevus, cancer immunotherapy Tecentriq and hemophilia medicine Hemlibra, all of which are expected to have peak sales of well over $1 billion annually.
Roche is counting on these and other medicines to help replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose patents have expired or will shortly, exposing them to cheaper competition.
Franz also told the newspaper that the United States, where prices for drugs are among the world’s highest, is supporting the bulk of the research and development cost for new, innovative drugs.
Asked if U.S. President Donald Trump’s pledge this year to tackle high drug prices will have an impact, Franz acknowledged that there could be a hit to the “innovation premium” that U.S. insurers and other funders pay for new drugs in America.
Radical changes to the model governing how medicines are reimbursed in the United States would likely lead to job cuts, he said.
“To put it bluntly, if the Americans were to adopt the Swiss price system, Roche would have to cut thousands of research jobs, also in Switzerland,” Franz said.
By John Miller
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.